CMS: Class 1 Innovative Drug Silevimig Injection Approved In China, Becoming The World's First Bispecific Antibody For Passive Immunization Against Rabies

(MENAFN - ACN NewsWire) CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies SHENZHEN, June ...